All In Biotech

Drug Trial Radar · NCT06477536

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

A Phase IIb, Long-Term Extension Study to Evaluate the Safety and Efficacy of HB0034 in the Treatment of Adult Subjects With Generalized Pustular Psoriasis

Last checked: Nov 19, 2026Latest source record: Feb 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

33

Planned (sponsor's estimate)

Start

Sep 2, 2024

Primary completion

Dec 30, 2025

Study completion Jun 30, 2026

Sponsor

Sponsor type
Industry
First posted
Jun 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase IIb, long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis (GPP).

Conditions

  • Generalized Pustular Psoriasis

Interventions

  • HB0034Drug

    300mg, i.v. Q4W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety endpoints include the proportion of subjects with TEAEsTime frame: 0-24 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital (PKUPH)

    Beijing, China · Recruiting

  • Peking University People's Hospital

    Beijing, China · Recruiting

  • The Second affiliated Hospital zhejiang University School of Medicine

    Hangzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.